Study shows safe outcomes for PCI performed in ambulatory surgery centers

The first study evaluating Medicare patients undergoing percutaneous coronary intervention (PCI) in ambulatory surgery centers (ASCs) demonstrated good safety outcomes, such as mortality and adverse event rates at 30 days, compared to outpatient hospital departments, but were less likely to use certain technologies. The late-breaking data were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2025 Scientific Sessions.

Ambulatory surgery centers (ASCs) are non-hospital facilities that provide same-day surgical or procedural care to often low-risk patients. Since Medicare began providing coverage for certain PCI procedures in ASCs in 2020, more of these procedures are being done outside the traditional hospital setting. The shift to ASCs can primarily be attributed to the potential for cost savings, innovation in clinical diagnostics, and the growing aging population in need of care. Between 2024 and 2034, ASC volume is anticipated to increase by 21%. However, little is known about the patient and procedural characteristics and outcomes of PCI in ASCs. 

This is the first study to investigate procedural volume trends, patient and procedural characteristics, and outcomes of outpatient PCI performed in ASCs within the Medicare population, benchmarked against hospital outpatient departments. Clinical settings (hospital inpatient, hospital outpatient [OP], and ASC) were determined by the Claim Place of Service codes; and the Social Vulnerability Index, a validated measure of socioeconomic status and community-level stressors developed by the CDC, was used.

Among 408,060 patients who underwent outpatient PCI from 2020 to 2022, 7,494 (1.8%) were in ASCs, and 400,566 (98.2%) were in hospital outpatient departments. The rate of PCIs in ASC increased from 0.01 per 10,000 person-years in 2018 to 0.87 in 2022. Patients treated in ASCs were more often in the Southern region of the U.S. and in socially vulnerable areas (36.6% vs. 21.9%), and fewer patients underwent multivessel PCI (3.0% vs. 5.9%). At 30 days, adverse events such as mortality, stroke, pericardial effusion and tamponade, and access-site bleeding were comparable between groups. Patients treated in the outpatient hospital setting had higher rates of all-cause hospitalization and acute myocardial infarction, while ASC patients had a higher rate of repeat PCI (OR 2.14).

Patients are drawn to care at ASCs due to the lower costs and greater convenience, which correlates to the shift we're seeing in PCIs being done at ASCs. We're also seeing a trend of physicians thoughtfully selecting patients to undergo PCIs in this setting – something we anticipate will increase in the future. Looking forward, participation in national registries, such as the American College of Cardiology's Cardiovascular ASC Registry suite, will be an important step toward establishing national quality benchmarks tailored to the risk profile of patients treated in the ASC setting."

Katerina Dangas, BMBCh, Research Fellow at the Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center in Boston, and lead author of the study

As the number of ASC PCI cases increases, continued investigation is warranted.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breast cancer survivors face accelerated aging tied to tumors and treatment